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Abstract: Platelet hyperactivation is involved in the established prothrombotic condition of metabolic
diseases such as Type 2 Diabetes Mellitus (T2DM) and familial hypercholesterolemia (HC), justifying
the therapy with aspirin, a suppressor of thromboxane synthesis through the irreversible inhibition of
cyclooxygenase-1 (COX-1), to prevent cardiovascular diseases. However, some patients on aspirin
show a higher than expected platelet reactivity due, at least in part, to a pro-oxidant milieu. The aim
of this study was to investigate platelet reactivity in T2DM (n = 103) or HC (n = 61) patients
(aspirin, 100 mg/day) and its correlation with biomarkers of redox function including the superoxide
anion scavenger superoxide dismutase (SOD) and the in vivo marker of oxidative stress urinary
8-iso-prostaglandin F2α. As results, in T2DM and HC subjects the prevalence of high on-aspirin
platelet reactivity was comparable when both non-COX-1-dependent and COX-1-dependent assays
were performed, and platelet reactivity is associated with a lower SOD activity that in a stepwise
linear regression appears as the only predictor of platelet reactivity. To conclude, in T2DM and HC,
similarly, the impairment of redox equilibrium associated with a decrease of SOD activity could
contribute to a suboptimal response to aspirin.
Keywords: platelets; oxidative stress; superoxide dismutase; aspirin; thromboxane; platelet function
analyzer-100
1. Introduction
Atherothrombosis is the primary cause of cardio- and cerebrovascular events in patients with
Type 2 Diabetes Mellitus (T2DM) and platelet hyperactivation plays a pivotal role in the initiation and
progression of thrombotic complications that follow the atherosclerotic plaque disruption [1–3].
Platelet activation is a multifactorial process where the platelet-platelet interaction provides a
further source of intracellular signaling associated with the release of pro-inflammatory and pro-
aggregating molecules, thus increasing the prothrombotic tendency.
Since the inhibition of platelet activation pathways with antiplatelet therapy is crucial for the
prevention of atherothrombotic diseases, aspirin (acetylsalicylic acid) has been extensively used as
medication in the prevention of cardiovascular events in T2DM patients due to its main ability to
suppress thromboxane A2 (TXA2) synthesis, a powerful activator of platelet response and thrombus
formation, by irreversibly inhibiting cyclooxygenase-1 (COX-1) activity [4,5].
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However, in spite of its wide acceptance and utilization, the clinical aspirin effectiveness in
protecting from vascular events has been questioned because of the occurrence of cerebro- and
cardiovascular events even in the presence of low-dose aspirin treatment both in primary [4] and
secondary prevention [5]. The role of biochemical and clinical features involved in the reduced aspirin
effect in T2DM is a still debated issue—it has been shown that in T2DM patients, either genetic factors
or secondary causes (metabolic disorders and/or inflammatory states) may be important contributors to
the diminished aspirin action [6], demonstrating that the benefits of aspirin treatment may be overcome
by aspirin-insensitive mechanisms of platelet activation [7,8].
In all cases, as a result of the insufficient inhibition of COX-1 activity by aspirin, a larger amount of
both serum and urinary excretion of TXA2 metabolites has been found and associated with increased
incidence of major adverse cardiovascular events [9–12].
Metabolic derangement in diabetes can account for the impairment of both endothelial and
platelet function with the expression and release of mediators involved in the atherogenic process
such as chemokines, adhesion molecules, and cytokines. Both acute and chronic hyperglycemia are
associated with platelet activation in T2DM [13] and, also, the urinary excretion rate of 11-dehydro-
TXB2 (11-dhTXB2) and 8-iso-prostaglandin F2α (8-iso-PGF2α), a reliable marker of oxidative stress,
correlate directly with metabolic control, suggesting a link between glycemic control, oxidative stress
and platelet activation [14], with the caution that urine 11-dhTXB2 is not only a marker of platelet
activity [15] but also a marker of inflammation, since it originates from other blood cells [16].
In normal conditions, a protective role in modulating redox status is exerted by superoxide
dismutase (SOD), a class of enzymes that catalyze the dismutation of the superoxide anion into
oxygen and hydrogen peroxide [17] and the extracellular SOD (EC-SOD or SOD3) is a major plasma
extracellular antioxidant enzyme [18].
Under oxidative stress conditions, both arachidonic acid (AA) and circulating low-density lipoprotein
(LDL), through a nonenzymatic process of peroxidation, increase the production of some biologically
active prostanoids able to influence platelet function [19]. In particular, abnormal 8-iso-PGF2α production
has been found to correlate with soluble CD40 Ligand (sCD40L) biosynthesis [20], a marker of in vivo
platelet activation, and is considered a crucial factor able to trigger a cascade of activation pathways
substantially contributing to increased platelet responsiveness to common agonists.
The increased oxidative stress and endothelial activation related to glucose excursions are strictly
associated with platelet hyperactivation [21–23].
Hypercholesterolemia (HC) per se predisposes to atherothrombotic complications through different
mechanisms including platelet hyperactivity [24] and a reduced cardioprotective action of aspirin [25].
In this context, the impaired platelet metabolism and intraplatelet signaling pathways as a result of the
influence of the concomitant metabolic and proatherogenic abnormalities may significantly contribute
to increase platelet reactivity [26] and reduce the inhibitory effects of aspirin.
The aim of this study was to establish in T2DM or primary HC the relationships between a pattern
of pro- and antioxidant, inflammation and endothelial dysfunction biomarkers and the presence of
high on-aspirin residual platelet reactivity.
2. Results
Taking into account that aspirin action specifically inhibits COX-1 activity and that the serum TXB2
measurement represents the most accurate COX-1-dependent test, we focused this study on patients
with serum TXB2 concentrations lower than 10 ng/mL, corresponding to more than 95% inhibition of
COX-1 activity [27]. We excluded four out of 65 HC and 10 out of 113 T2DM patients from the final
analysis since they showed serum TXB2 concentrations higher than 10 ng/mL, thus indicating patients
with true resistance to aspirin, poor patient compliance or inability of once-daily dose of aspirin to
inhibit newly formed platelets due to increased platelet turnover.
Main clinical and laboratory characteristics of the investigated subjects are summarized in Table 1.
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Table 1. Clinical characteristics of primary hypercholesterolemia (HC) or Type 2 Diabetes Mellitus
(T2DM) patients, n = 164.
HC (n = 61) T2DM (n = 103) p
Female gender, n (%) 28 (46) 50 (49) 0.87
Age (years) 63.9 ± 7.5 64.5 ± 7.0 0.58
BMI (kg/m2) 27.7 ± 3.2 29.3 ± 4.0 0.008
Fasting Glucose (mg/dL) 95.9 ± 10.1 159.5 ± 42 0.0001
HbA1c (%) 5.9 ± 0.33 7.99 ± 1.2 0.0001
TC (mg/dL) 194.2 ± 33.9 177.4 ± 37.7 0.005
HDL-C (mg/dL) 52.4 ± 10.4 43.8 ± 10.3 0.0001
TG (mg/dL) 126.1 ± 48.5 136.3 ± 66.2 0.29
LDL-C (mg/dL) 116.5 ± 32.4 103.2 ± 38.7 0.019
PLT (×103/µL) 231 ± 42.3 239 ± 48 0.3
WBC (×103/µL) 7.1 ± 1.6 7.1 ± 1.8 0.92
RBC (×103/µL) 4.8 ± 0.44 4.7 ± 0.50 0.5
HCT (%) 41.9 ± 2.9 42.5 ± 3.9 0.29
MPV (fl) 8.4 ± 1.2 8.3 ± 0.9 0.53
vWF (%) 130.2 ± 56 123 ± 61 0.44
Creatinine 74.6 ± 20.3 75.3 ± 27.9 0.87
SBP (mmHg) 129.9 ± 10.6 134.3 ± 10.9 0.013




28 (43) 26 (25) 0.62
Current smokers, n (%) 14 (23) 28 (27) 0.23
Medication use, n (%)
Statins 45 (74) 70 (68) 0.006
Antihypertensives 28 (46) 81 (79) 0.0001
Insulin 0 24 (23) N/A
Metformin 0 84 (82) N/A
Any oral antidiabetic drugs 0 68 (66) N/A
Data are presented as mean ± SD, otherwise specified. BMI: body mass index; HbA1c: glycosylated hemoglobin;
TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein
cholesterol; WBC: white blood cells; RBC: red blood cells; HCT: hematocrit; MPV: mean platelet volume; vWF:
von Willebrand Factor; SBP: systolic blood pressure; DBP: diastolic blood pressure; N/A: not applicable.
In comparison with HC, T2DM patients showed significantly higher values of body mass index
(BMI) (p = 0.008), glycosylated hemoglobin (HbA1c) (p < 0.0001), fasting blood glucose (p < 0.0001),
and systolic blood pressure (p = 0.013) and lower levels of total cholesterol (TC) (p = 0.005), LDL-C (p = 0.019),
and high-density lipoprotein cholesterol (HDL-C) (p < 0.0001).
2.1. Residual On-Aspirin Platelet Reactivity Assays in HC and T2DM Patients
Aspirin intake, as expected, reduced platelet adhesion and aggregation under shear stress
conditions, as mirrored by the prolongation of Platelet Function Analyzer (PFA)-100 closure times
when collagen/epinephrine (CEPI) but not collagen/adenosine diphosphate (ADP) (CADP) PFA-100
cartridges were used. CEPI PFA-100 median values were 292 sec for T2DM and 275 sec for HC subjects
(p = ns) (Figure 1A).
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Figure 1. Box-plots showing collagen/epinephrine (CEPI) Platelet Function Analyzer-100 (PFA-100)
closure time values in primary hypercholesterolemia (HC) and Type 2 Diabetes Mellitus (T2DM)
patients (A) and in HC and T2DM patients stratified for the absence (-) or the presence (+) of high
on-aspirin platelet reactivity (HPR) (B). Horizontal dotted line denotes cut-off value for residual platelet
reactivity despite aspirin intake. Solid lines, median values; boxes, interquartile range; whiskers,
nonoutlier range; open circles, outliers.
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When stratified for the absence (HPR-) or the presence of high platelet reactivity (HPR+) based on
the response to CEPI PFA-100 (cut-off 193 sec), the percentage of HPR+ in T2DM and HC subjects was
similar (23% and 25%, respectively, p = ns) (Figure 1B) and within each group closure time values were
significantly different between HPR+ and HPR- (p < 0.0001).
CADP PFA-100 closure time median values were 89 sec for HC and 85 sec for T2DM patients
(p = ns) without significant differences between HPR- and HPR+ within each study group.
Figure 2 shows in HC and T2DM patients the distribution of light transmission aggregation (LTA)
tests in response to AA (Figure 2A), collagen (Figure 2B), and ADP (Figure 2C) with the dotted line
which denotes the cut-off value for residual platelet reactivity despite aspirin intake and separates
HPR+ (above the line) from HPR- (below the line) subjects. Accordingly with these limit values, in HC
and T2DM subjects, the percentage of HPR+ was, respectively, 11% and 12% with LTA-AA (p = ns),









Figure 2 shows  in HC and T2DM patients  the distribution of  light  transmission aggregation 
(LTA) tests in response to AA (Figure 2A), collagen (Figure 2B), and ADP (Figure 2C) with the dotted 















































































































Figure 2. Distribution of light platelet aggregation (LTA) to arachidonic acid (AA) (A), collagen (B),
adenosine diphosphate (ADP) (C) and of urinary 11-dehydro-thromboxane B2 (11-dhTXB2) levels (D)
in primary hy ercholesterolemia (HC) and Type 2 Diabetes Mellitus (T2DM) patients. Horizontal
dotted line denotes, for ach platelet functio test, the cut-off value which separates subjects without (-)
or with (+) high n-aspi in platelet r activity (HPR).
A persistent platelet activation was also evaluated by measuring the urinary 11-dhTXB2 (Figure 2D)
given that 80% of urinary 11-dhTXB2 is platelet-derived [28]. Accordingly with a cut-off value of
≤1500 pg for 11-dhTXB2/mg creatinine corres onding to a good aspirin effect [29], the percentage of
HPR+ was 25% in HC and 26% in T2DM patients (p = ns).
2.2. Metabolic Parameters and Biomarkers of Oxidative Stress, Inflammation, and Platelet Activation in HPR+
vs. HPR- According to CEPI PFA-100
We chose the respo se to CEPI PFA-1 0 as the parameter to distinguish HPR- from HPR+ and to
compare them in terms of clinical and laboratory data within HC and T2DM patient groups. Indeed,
among the platelet tests used here, PFA-100 is the most physiological since it was performed in whole
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blood and was potentially influenced by circulating biochemical factors, inflammatory and pro-oxidant
molecules. Furthermore, it is rapid and easy to use, approved for measuring platelet dysfunction and
widely used to detect aspirin response in clinical settings [30].
Whilst no significant difference was found between HPR+ and HPR- within HC subjects as far as
the main clinical and metabolic parameters are concerned, T2DM HPR+ differed from HPR- for higher
levels of TC (p = 0.005) and LDL-C (p = 0.013) (Table 2).
Table 2. Clinical characteristics of primary hypercholesterolemia (HC) or Type 2 Diabetes Mellitus
(T2DM) patients stratified on the basis of presence (+) or absence (-) of high on-aspirin platelet
reactivity (HPR).
HC T2DM
HPR- (n = 46) HPR+ (n = 15) p HPR- (n = 79) HPR+ (n = 24) p
Female gender, n (%) 20 (43) 8 (53) 0.78 40 (51) 10 (42) 0.63
Age (years) 63.9 ± 7.2 63.8 ± 8.5 0.96 65 ± 7.1 63 ± 6.7 0.21
BMI (kg/m2) 27.7 ± 3.4 27.5 ± 2.6 0.79 30 ± 4 28.5 ± 2.9 0.16
Fasting Glucose (mg/dL) 96.2 ± 11 94.9 ± 7.9 0.65 159 ± 38 162.3 ± 54 0.81
HbA1c (%) 5.9 ± 0.4 5.8 ± 0.24 0.26 8 ± 1.1 7.9 ± 1.4 0.62
TC (mg/dL) 193 ± 36.3 197.5 ± 26.2 0.66 172 ± 37 196 ± 34 0.005
HDL-C (mg/dL) 51.7 ± 10.2 54.7 ± 11.2 0.32 44 ± 11 42 ± 9 0.27
TG (mg/dL) 130 ± 51 114.1 ± 39.6 0.27 134 ± 68 144 ± 60 0.52
LDL-C (mg/dL) 115.4 ± 35 120 ± 23.4 0.63 99 ± 36 120 ± 43 0.013
PLT (×103/µL) 228 ± 42 238.3 ± 42.8 0.45 241 ± 51 229 ± 36 0.2
WBC (×103/µL) 7.09 ± 1.4 7.2 ± 2.1 0.92 7.13 ± 1.9 6.9 ± 1.6 0.58
RBC (×103/µL) 4.8 ± 0.5 4.9 ± 0.41 0.48 4.7 ± 0.5 4.8 ± 0.5 0.71
HCT (%) 41.4 ± 2.4 43.4 ± 3.6 0.063 42 ± 3.7 44 ± 4 0.17
MPV (fl) 8.4 ± 1.1 8.6 ± 1.4 0.51 8.3 ± 0.9 8.6 ± 1 0.22
vWF (%) 127 ± 59 141.6 ± 50 0.37 122 ± 58 126 ± 68 0.78
SBP (mmHg) 130.1 ± 10.6 129.3 ± 11 0.8 135 ± 10 133 ± 13 0.42
DBP (mmHg) 77.4 ± 7.1 76.7 ± 7 0.73 77.2 ± 7.4 76 ± 6.5 0.65
Data are presented as mean ± SD, otherwise specified. BMI: body mass index; HbA1c: glycosylated hemoglobin;
TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein
cholesterol; WBC: white blood cells; RBC: red blood cells; HCT: hematocrit; MPV: mean platelet volume; vWF:
von Willebrand Factor; SBP: systolic blood pressure; DBP: diastolic blood pressure.
When oxidative stress, inflammation and platelet activation markers were investigated (Table 3),
in comparison with HC, T2DM subjects showed significant higher circulating levels of—(i) the in vivo
oxidative stress marker 8-iso-PGF2α (p = 0.016), (ii) the in vivo platelet activation marker sCD40L
(p < 0.0001), (iii) the subclinical inflammatory marker interleukin-6 (IL-6) (p = 0.0001).
Table 3. Biomarkers of oxidative stress, endothelial dysfunction, platelet activation, atherogenesis, and
inflammation in primary hypercholesterolemia (HC) or Type 2 Diabetes Mellitus (T2DM) patients, n = 164.
HC (n = 61) T2DM (n = 103) p
SOD (U/mL) 0.23 ± 0.05 0.22 ± 0.05 0.4
8-iso-PGF2α (pmol/mmol creat) 141 ± 76 184 ± 126 0.016
sE-Selectin (pg/mL) 38.3 ± 21 48 ± 36 0.1
sICAM (ng/mL) 447 ± 61 457 ± 48 0.27
sP-Selectin (pg/mL) 174 ± 96 187 ± 62 0.298
sCD40L (pg/mL) 3.4 ± 4.2 12 ± 9.3 0.0001
IL-6 (pg/mL) 7.5 ± 4 9.7 ± 6 0.016
sRAGE (ng/mL) 1111 ± 640 826 ± 327 0.0001
TXB2 (ng/mL) 4.03 ± 2.3 4.4 ± 2.9 0.381
11-dhTXB2 (pg/mg creat) 1388 ± 591 1713 ± 1454 0.049
Data are presented as mean ± SD. SOD: superoxide dismutase; 8-iso-PGF2α: 8-iso-prostaglandin F2α; IL-6:
interleukin-6; sRAGE: soluble Receptor of Advanced Glycation End Products; TXB2: thromboxane B2; 11-dhTXB2:
11-dehydro-thromboxane B2.
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Furthermore, T2DM patients showed higher levels of 11-dhTXB2 (p = 0.049) and lower concentrations
of the antiatherogenic soluble RAGE (sRAGE) (p < 0.0001). A significant direct correlation was found
between 8-iso-PGF2α and fasting glucose (r = 0.250, p = 0.002) and HbA1c (r = 0.231, p = 0.004),
thus indicating the effect of metabolic control on the increase of oxidative stress.
With regard to SOD activity, sCD40L, soluble E-selectin (sE-selectin) and soluble Intercellular Adhesion
Molecule (sICAM) showed no statistically significant differences between HC and T2DM patients.
When subjects within each study population were stratified in HPR+ and HPR- according to their
response to CEPI PFA-100 (Table 4), we found that HPR+ differed from HPR- for—(i) SOD activity
(p = 0.002), soluble p-selectin (sP-selectin) (p = 0.001), sRAGE (p = 0.004), and 11-dhTXB2 (p = 0.035)
levels in HC patients; (ii) SOD activity (p = 0.0001), 8-iso-PGF2α (p < 0.0001), sCD40L (p = 0.003),
and 11-dhTXB2 (p = 0.042) in T2DM patients.
Table 4. Biomarkers of oxidative stress, endothelial dysfunction, platelet activation, atherogenesis,
and inflammation in primary hypercholesterolemia (HC) or Type 2 Diabetes Mellitus (T2DM) patients,
stratified on the basis of presence (+) or absence (-) of high on-aspirin platelet reactivity (HPR).
HC T2DM
HPR- HPR+ p HPR- HPR+ p
SOD (U/mL) 0.24 ± 0.04 0.18 ± 0.06 0.002 0.23 ± 0.05 0.18 ± 0.04 0.0001
8-iso-PGF2α (pmol/mmol Creat) 140.1 ± 81 142 ± 61 0.92 161 ± 132 259 ± 63 0.0001
sE-Selectin (pg/mL) 37.7 ± 23 39.7 ± 13.5 0.73 46.1 ± 35 53.6 ± 37 0.39
sICAM (ng/mL) 450 ± 58 440 ± 69.3 0.64 457.02 ± 52 459 ± 36 0.89
sP-Selectin (pg/mL) 155 ± 91 245 ± 79.3 0.001 184 ± 63 196 ± 56 0.41
sCD40L (pg/mL) 2.8 ± 2.1 5.5 ± 7.7 0.052 10.8 ± 9.2 15.7 ± 9 0.003
IL-6 (pg/mL) 7.5 ± 4.6 7.5 ± 3.2 0.95 9.5 ± 6.1 10.2 ± 6.1 0.63
sRAGE (ng/mL) 1225 ± 694 807 ± 324 0.004 841 ± 355 777 ± 214 0.41
TXB2 (ng/mL) 3.8 ± 2.3 4.85 ± 2.2 0.12 4.1 ± 2.9 5.4 ± 2.6 0.59
11-dhTXB2 (pg/mg creat) 1270 ± 472 1753 ± 770 0.037 1550 ± 1270 2230 ± 1675 0.042
Data are presented as mean ± SD. SOD: superoxide dismutase; 8-iso-PGF2α: 8-iso-prostaglandin F2α; IL-6:
interleukin-6; sRAGE: soluble Receptor of Advanced Glycation End Products; TXB2: thromboxane B2; 11-dhTXB2:
11-dehydro-thromboxane B2.
2.3. Correlation Analyses
In HC subjects—(i) CEPI PFA-100 closure times significantly correlated with SOD (r = 0.507,
p < 0.0001), sRAGE (r = 0.309, p = 0.022), and sP-selectin (r = −0.351, p < 0.006), (ii) SOD inversely
correlated with 11-dhTXB2 (r = −0.379, p = 0.003), and LTA-AA (r = 0.368, p = 0.004), (Figure 3).
In T2DM subjects—(i) CEPI PFA-100 closure times significantly correlated with LDL-C (r = −0.240,
p = 0.015), SOD (r = 0.357, p < 0.0001), 11-dhTXB2 (r = −0.324, p = 0.001), and 8-iso-PGF2α (r = −0.332,
p = 0.001); (ii) SOD inversely correlated with 11-dhTXB2 (r = −0.195, p = 0.05), 8-iso-PGF2α (r = −0.207,
p = 0.038), LTA-AA (r = −0.201, p = 0.043), and LTA-collagen (r = −0.182, p = 0.067) (Figure 4).































































































































































































































































































































































































Figure 3. Univariate regression analysis of collagen/epinephrine (CEPI) Platelet Function Analyzer-100 (PFA-100) and superoxide dismutase (SOD) with biomarkers
and platelet aggregation tests in subjects with primary hypercholesterolemia (HC). Hb 1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholest ol;
8-iso-PGF2α, 8-iso-pr staglandin F2α; IL-6, inte leukin-6; 11-d TXB2, 11-dehydro-thromboxane B2; LTA, light transmission aggregation.




























































































































































































































































































































































































Figure 4. Univariate regression analysis of collagen/epinephrine (CEPI) Platelet Function Analyzer-100 (PFA-100) and superoxide dismutase (SOD) with biomarkers
and platelet aggregation tests in subjects with Type 2 Diabetes Mellitus (T2DM). HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol;
8-iso-PGF2α, 8-iso-prostaglandin F2α; IL-6, interleukin-6; 11-dhTXB2, 11-dehydro-thromboxane B2; LTA, light transmission aggregation.
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Interestingly, a univariate regression analysis performed on the whole population showed that
(i) SOD significantly correlated with LDL-C (r = −0.160, p = 0.0041), 8-iso-PGF2α (r = −0.158, p = 0.05),
11-dhTXB2 (r = −0.213, p = 0.006). A stepwise regression analysis including clinical and laboratory data
that differed between HC and T2DM patients and between HPR- and HPR+ within each group (BMI,
HbA1c, fasting glucose, TC, HDL-C, LDL-C, SOD, sRAGE, 8-iso-PGF2α, IL-6, sCD40L), entered as
independent variables, and CEPI PFA-100 as a dependent variable showed that only SOD significantly
predicted platelet reactivity according to CEPI PFA-100 response in both HC (t = 5.941, β = 0.632,
p < 0.0001) and T2DM (t = 2.873, β = 0.298, p = 0.005) patients.
3. Discussion
The main findings of this study are that—(i) T2DM and primary HC patients show comparable
prevalence of high on-aspirin platelet reactivity when the non-COX-1-dependent CEPI PFA-100 and
COX-1-dependent LTA-AA, LTA-collagen, urinary 11-dhTXB2 assays were performed; (ii) compared
to HPR-, HPR+ subjects with T2DM or HC showed an imbalance of redox status corresponding to a
lower activity of the oxidant scavenger SOD; (iii) SOD positively correlates with CEPI PFA-100 closure
times and a stepwise linear regression yielded a model in which only SOD predicts platelet reactivity
in both T2DM and HC.
Although an impaired aspirin ability to inhibit platelet aggregation has been frequently observed
in T2DM if compared with the general population [31,32], in this study we show that T2DM and primary
HC patients, all on 100 mg/d aspirin treatment, display a similar prevalence for HPR+ in most of the
in vitro assays used to test platelet sensitivity to the inhibitory effects of aspirin. Notably, we excluded
from the investigation subjects with serum TXB2 levels >10 ng/mL that mirror the failure of aspirin to
effectively inhibit COX-1 activity for true “aspirin resistance”, poor compliance or insufficient aspirin
dose effectiveness when platelet turnover is increased [33]; instead, we focused our investigations on
platelets in which COX-1 is sufficiently inhibited by aspirin and the platelet reactivity is not strictly
COX-1-dependent. After that, serum TXB2 concentrations did not differ between T2DM and HC
patients unlike urinary 11-dhTXB2 levels, which provide a reliable information on the systemic rate of
in vivo TXA2 biosynthesis derived from platelets and inflammatory cells through COX-2-dependent
mechanisms, were higher in T2DM. Interestingly, our T2DM patients also showed higher levels of
sCD40L and 8-iso-PGF2α and the positive correlation between sCD40L and 11-dhTXB2 and 8-iso-PGF2α
(data not shown) confirms that CD40L release occurs during TXA2-dependent activation and is involved
in the increased oxidant stress and lipid peroxidation in T2DM [20], respectively. The significant
direct correlation between 8-iso-PGF2α and HbA1c [19] may explain, at least in part, why T2DM
patients show greater levels of 8-iso-PGF2αthan HC, despite not explaining why 8-iso-PGF2α but not
HbA1c values, significantly differed between HPR+ and HPR- in T2DM. Of note, increased levels of
sCD40L and 11-dhTXB2 characterized HPR+ in both T2DM and HC suggesting common biochemical
mechanisms linking residual platelet reactivity and inflammation. We also observed that T2DM
compared to HC subjects are also characterized by lower circulating levels of sRAGE, which is known
to act as a protective factor against the deleterious effects of inflammation and oxidative stress [34].
This inflammatory environment also promotes lipid peroxidation with consequent activation of platelets
and furthers oxidative stress, which could contribute to enhanced urinary excretion of 8-iso-PGF2α
more in T2DM than in HC subjects [35–37]. In light of this, it cannot be excluded that the lower
sRAGE levels found in HPR+ subjects with HC may have a role in the higher plasma concentrations of
sP-selectin observed in the same subjects.
We observed that the prevalence of HPR+ subjects in T2DM and HC is comparable when platelet
reactivity was evaluated by CEPI PFA-100, LTA-AA, LTA-collagen, and 11-dhTXB2 levels, whereas
a higher percentage of HPR+ subjects resulted in T2DM than in HC subjects when LTA-ADP was
performed. Indeed, LTA-ADP, even if used to measure platelet sensitivity to aspirin, is not specific at
measuring COX-1 activity and shows low agreement with LTA-AA and serum TXB2 [38].
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The heterogeneity in the response and the different incidence of HPR+ among these tests are not
surprising and confirm the clear difference in the ability of each of these tests to detect the on-aspirin
treatment residual platelet reactivity [38]. Among them, LTA-AA is the COX-1-dependent test that
better agrees with serum TXB2 because AA agonist exploits the specific pathway affected by aspirin
and it is still considered the gold standard of platelet function. However, other mechanisms of platelet
activation are highly likely to occur within whole blood in which COX-1 inhibition by aspirin can be
bypassed. CEPI PFA-100, a non-COX-1-dependent test carried out in whole blood, is widely available,
rapid and simple to use even though it tends to overestimate the prevalence of high residual platelet
reactivity [39]. Nevertheless, lower CEPI PFA-100 closure times denoting platelet hyporesponsiveness
to aspirin are clinically associated with increased vascular events [40]. In light of this, we used the
response to CEPI PFA-100 as the phenotypic identifier for comparison of clinical and laboratory data
between HPR- and HPR+ subjects within T2DM and HC patient groups.
To the best of our knowledge, we show for the first time that a high on-aspirin residual platelet
reactivity based on CEPI PFA-100 method in both T2DM and HC patients is associated with a
reduced activity of the extracellular SOD, a major extracellular antioxidant enzyme deeply involved
in modulating the cell redox status and highly expressed in blood vessels, particularly in arterial
walls where it represents up to 70% of the total SOD activity [41]. Indeed, differently from reactive
oxygen species (ROS)-generating enzymes, conflicting results came from human studies that evaluated
the relationship between diseases and antioxidant enzymes given that for ROS scavenger enzymes,
decreased or increased activities (or levels) have been reported [42–46].
It is important to underline that, by catalyzing the dismutation of superoxide into oxygen
and hydrogen peroxide, SOD can acts as a pro-oxidant, thus other antioxidant enzymes, such as
catalase and glutathione peroxidase, are normally needed to avoid a redox imbalance with consequent
dangerous effects due to increased oxidant milieu [47]. Oxidative stress plays a major role in the
development of vascular complications in different clinical settings and the extracellular SOD exerts
vascular protection against oxidant species [41]. Interestingly, in our study, in both T2DM and HC,
SOD activity is lower in HPR+ than in HPR- subjects and positively correlates with CEPI PFA-100
closure times, thus suggesting the implication of this antioxidant enzyme in influencing platelet
function. Furthermore, a negative correlation was found between SOD and 11-dhTXB2 in HC, between
SOD and 11-dhTXB2 and 8-iso-PGF2αin T2DM. The relationship between SOD and 11-dhTXB2 is likely
to be attributable to the role of oxidant species, such as hydrogen peroxide, which are a stimulus for
the production of platelet thromboxane A2 [48], thus justifying, at least in part, the finding that animals
deficient in antioxidants showed enhanced platelet activation, platelet-rich thrombi, and occluded
vessels to a greater extent than wild-type ones [49].
As known, metabolic diseases such as T2DM and HC are associated with an oxidative stress
milieu as a consequence of intracellular hyperglycemia or increased oxidation of fatty acids [50] and
superoxide, in particular, is the initial oxygen free radical formed by the mitochondria, which is then
converted to other more reactive species that can damage cells [51]. It is known that when ROS
generation exceeds the capacity of the antioxidant defense systems and/or in the presence of a reduction
of antioxidant enzymes, oxidative stress occurs and represents the primary cause of endothelial
dysfunction and vascular damage in metabolic diseases [52]. A large body of evidence supports
the close link between increased oxidative stress, which characterizes both T2DM and HC, and a
less-than-expected response to aspirin, with different mechanisms [53]. Actually, chronic oxidative
stress [54] and decreased antioxidant capacity [55] have been documented in diabetes but, for the first
time, we show plasma SOD as a contributor to promote redox status imbalance and it appears as
the only predictor of CEPI PFA-100 in on-aspirin-treated T2DM and primary HC patients. Of course,
further studies to fully elucidate in these subjects not only the radical scavenging enzyme activity but
also the plasma nonenzymatic antioxidant capacity would be required to better define the influence of
the impaired redox equilibrium on platelet hyper-reactivity.
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It is currently recognized that HC induces phenotypic vascular changes consistent with oxidative
and nitrosative stresses. Once formed, superoxide participates in a number of reactions, yielding various
free radicals, such as hydrogen peroxide, peroxynitrite, or oxidized-LDL. In particular, LDL particles
in their native form induce hypersensitivity of platelets to agonists resulting in increased aggregation
and secretion responses whereas, after oxidation, they become independent platelet activators in
stirred platelet suspensions [56,57]. In this study, T2DM, as compared with HC, showed lower LDL-C
levels. However, increased LDL-C characterizes HPR+ T2DM, compared with HPR- T2DM subjects,
and CEPI PFA-100 is significantly and inversely correlated with LDL-C in T2DM but not in HC
subjects, thus supporting the hypothesis that a pro-oxidant milieu triggered by hyperglycemia may
amplify platelet activation via specific oxidized-LDL receptors and promote hyporesponsiveness to
aspirin [58]. Noteworthy, a significant inverse correlation was found between SOD activity and LDL-C
in a regression analysis including both T2DM and HC subjects, thus suggesting that hyperlipidemia is
commonly involved in diminishing aspirin responsiveness in poorly controlled diabetes subjects and
HC patients [59].
Some limitations of the study have to be taken into consideration. Firstly, classification of HPR+
and HPR- and their relationship with biomarkers were based on a single platelet assay. One could
argue that the conclusions drawn are highly dependent on the test used and sometimes results obtained
from different assays are not in agreement. Secondly, subjects of this study were all on 100 mg/day
aspirin. Whether higher doses or increasing the frequency of aspirin administration from once to twice
daily could be beneficial on plasma SOD effects on platelet function remains to be investigated.
4. Materials and Methods
4.1. Study Population
In this observational study, the potential population was initially represented by a total of
178 patients all on aspirin (100 mg/d), including patients affected by T2DM (n = 113) and patients with
primary HC (n = 65). Patients were consecutively enrolled and diagnosis of T2DM was in accordance
with the American Diabetes Association definition [60], whereas diagnosis of primary HC was in
accordance with the Adult Treatment Panel (ATP) III criteria [61]. Exclusion criteria were concurrent
therapy interfering with platelet function (i.e., nonsteroidal anti-inflammatory drugs, anticoagulants,
P2Y12 inhibitors, COX-2 inhibitors), acute coronary syndrome or coronary revascularization procedures
in the previous 12 months, active infections, inflammatory diseases, known platelet dysfunction or
thrombocytopenia (<100 × 109 platelets/L). The study was approved by the Ethics Committee of the
San Luigi Gonzaga Hospital (Project identification code: 213/INT, 3 June 2008). Written informed
consent was obtained from all participants
4.2. Laboratory Measurements
Blood and urine samples for the determination of the biochemical parameters and platelet assays
were collected after at least a 12 h overnight fast between 8:00 and 9:00 A.M., 18 h after the ingestion of
the last aspirin dose for the determination of the investigated biochemical parameters and platelet
assays. HbA1c was measured by automated high-performance liquid chromatography (HPLC) and
expressed as percentage. Blood glucose levels were evaluated by glucose oxidase method. Standard
laboratory techniques were used to determine TC, HDL-C, triglycerides (TG), and performed by
the central laboratory of our Hospital. LDL-C levels were estimated with the Friedewald formula.
For urinary metabolites, 24-h urine was collected and samples were added with the antioxidant
4-hydroxy-Tempo (1 mmol/L) (Sigma Chemical Co., St. Louis, MO, USA) and stored at −80 ◦C until
use. Von Willebrand Factor (VWF) antigen concentrations were measured in citrated human plasma by
an enzyme-linked immunosorbent assay (ELISA) (Corgenix Inc., Broomfield, CO, USA) and expressed
in relative percent relative to pooled normal plasma.
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For platelet assays, blood was drawn into evacuated tubes containing 3.8% Na-citrate and
processed within 2 h of collection. For the other circulating parameters, supernatants (serum or plasma)
were stored at −80 ◦C until use.
4.3. Platelet Assays
4.3.1. PFA-100
PFA-100 (Siemens Healthcare Diagnostic Products GmbH, Marburg, Germany) assay with CEPI
cartridge was utilized to assess aspirin-sensitivity among patients. PFA-100 is a point-of-care device
that by simulating the in vivo primary haemostasis, records the time up to a maximum of 300 s needed
for a whole blood sample to form a platelet plug closing an aperture on a membrane coated with
agonists. Furthermore, closure time in the presence of CADP cartridge was also performed in each
subject to exclude platelet dysfunction not dependent on aspirin. We categorized HPR+ patients with
CEPI PFA-100 closure times < 193 s (the manufacturer’s lower limit of the normal range for aspirin-free
healthy controls).
4.3.2. Platelet Aggregation
To perform LTA in platelet-rich plasma (PRP) as described by Born [62], whole blood samples
were centrifuged by using the Platelet Function Centrifuge (BioData Corporation, Horsham, PA, USA),
designed to provide a rapid separation of PRP by a centrifugation for 30 sec and of platelet-poor
plasma by a further centrifugation for 120 sec. Platelet aggregations in PRP were carried out using an
eight-channel aggregation system (Platelet Aggregation Profiler, Model PAP-8, BioData Corporation),
recorded for 5 min after agonist addition and expressed as % of maximal light transmittance. Platelets
were stimulated by AA (0.5 mg/L) (Sigma, St. Louis, MO, USA), ADP (10 µmol/L) (Sigma, St. Louis,
MO, USA), and collagen (4 mg/L) (Mascia Brunelli, Milan, Italy). Taking into account the cut-off values
most frequently used in the past and associated with increased risk of suffering from adverse cardiac
events despite daily aspirin intake, subjects in this study were considered HPR+ in the presence of
LTA-AA ≥ 20%, LTA-collagen ≥ 60%, and LTA-ADP ≥ 70% [63–66].
4.3.3. Thromboxane Metabolites
Platelet maximal COX-1-dependent biosynthetical capacity was evaluated by measuring serum
TXB2 concentrations by ELISA kit (Cayman Chemicals, Ann Arbor, MI, USA). The detection limit of
the assay was 0.2 ng/mL.
The systemic endogenous production of TXB2 was evaluated by measuring urinary 11-dhTXB2
concentrations by ELISA kit (AspirinWorks Test kit, Corgenix, Inc., Broomfield, CO, USA) according to
the manufacturer’s instructions and 11-dhTXB2 concentrations were normalized for urinary creatinine
concentrations. The detection limit of the assay was 11 pg/mL.
4.4. Biochemical Parameters
4.4.1. Inflammation, Endothelial Dysfunction and In Vivo Platelet Activation
Circulating levels of the following parameters were measured—(i) IL-6, as marker of subclinical
inflammation; (ii) sRAGE, as antiatherogenic marker; (iii) sE-selectin and sICAM, as markers of
endothelial dysfunction; (iv) sCD-40L and sP-selectin, as markers of in vivo platelet activation.
IL-6 and sCD40L concentrations were simultaneously quantified in the same plasma sample
by Milliplex Map kit (Millipore Corporation, Burlington, MA, USA) based on the Luminex xMAP
technology performing immunoassays on the surface of fluorescent-coated magnetic beads. Plasma
concentrations of sRAGE, sICAM, sE-selectin, sP-selectin were measured by ELISA kits (Bender
MedSystem, Vienna, Austria).
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4.4.2. Oxidative Stress
To evaluate the antioxidant potential to scavenge the main circulating ROS, plasma extracellular
SOD (or SOD3) activity was measured by using a SOD assay kit (Cayman Chemical Company,
Ann Arbor, MI, USA) and expressed as U/mL.
The measurement of the free radical-catalyzed lipid peroxidation product of AA 8-iso-PGF2α is
generally accepted as a reliable biomarker of oxidative stress [67,68]. The assay for the measurement
of urinary levels of 8-iso-PGF2α was performed by using a competitive ELISA kit (Oxford Biomedical
Research, Rochester Hills, MI, USA) and 8-iso-PGF2αconcentrations were normalized for urinary
creatinine concentrations.
4.5. Statistical Analysis
All statistical analyses were performed using SPSS 26.0 for Windows (SPSS Institute, Chicago,
IL, USA). Values in the text and figures are expressed as mean ± SD or median, according to their
distributions. Variable differences were tested by unpaired Student t test for normally distributed data
or Mann–Whitney U-test for non-Gaussian data distribution. Differences in categorical variables were
performed by using contingency tables and X2 or Fisher’s exact test. Results concerning PFA-100 were
evaluated with the nonparametric Wilcoxon signed rank test since closure time is a harmonic variable
with a maximum of 300 sec, which does not fluctuate proportionally within the scale. Pearson’s
or Spearman correlation coefficients were used to examine the significance of correlation between
variables, as appropriate. A multiple linear regression analysis, with variables significantly related to
CEPI PFA-100 at univariate analysis, was performed to identify predictors of CEPI PFA-100. Results
were considered significant for p < 0.05.
5. Conclusions
A comparable prevalence of high residual platelet reactivity was observed in T2DM and primary
HC patients when the LTA-AA, LTA-collagen, urinary 11-dhTXB2 levels and CEPI PFA-100 were
performed. A decreased activity of plasma extracellular SOD characterizes HPR+ subjects in both
T2DM and HC and only SOD significantly predicted platelet reactivity according to platelet response
to CEPI PFA-100. To conclude, in T2DM and HC, similarly, the impairment of redox equilibrium
associated with a decrease of SOD activity could contribute to a suboptimal response to aspirin.
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